Top

Published in:

Open Access 01-12-2022 | Alkaloids | Correction

Correction: Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets

Authors: Rui Qin, Feng‑Ming You, Qian Zhao, Xin Xie, Cheng Peng, Gu Zhan, Bo Han

Published in: Journal of Hematology & Oncology | Issue 1/2022

Excerpt

The original article [1] mistakenly omitted co-corresponding authorship of co-author, Gu Zhan. This has since been restored. …

Qin R, et al. Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets. J Hematol Oncol. 2022;15:133. https://doi.org/10.1186/s13045-022-01350-z.CrossRefPubMedPubMedCentral

Title: Correction: Naturally derived indole alkaloids targeting regulated cell death (RCD) for cancer therapy: from molecular mechanisms to potential therapeutic targets
Authors: Rui Qin
Feng‑Ming You
Qian Zhao
Xin Xie
Cheng Peng
Gu Zhan
Bo Han
Publication date: 01-12-2022
Publisher: BioMed Central
Keywords: Alkaloids
Alkaloids
Cancer Therapy
Published in: Journal of Hematology & Oncology / Issue 1/2022
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/s13045-022-01371-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 1/2022

Metabolic characteristics and prognostic differentiation of aggressive lymphoma using one-month post-CAR-T FDG PET/CT

Emerging role of RNA sensors in tumor microenvironment and immunotherapy

Randomized phase 2 trial of intravenous oncolytic virus JX-594 combined with low-dose cyclophosphamide in patients with advanced soft-tissue sarcoma

The molecular mechanisms and therapeutic strategies of EMT in tumor progression and metastasis

Efficacy and safety of CPX-351 versus 7 + 3 chemotherapy by European LeukemiaNet 2017 risk subgroups in older adults with newly diagnosed, high-risk/secondary AML: post hoc analysis of a randomized, phase 3 trial

The dual role of autophagy in acute myeloid leukemia

Keynote webinar | Spotlight on antibody–drug conjugates in cancer